Navigation Links
Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
Date:6/13/2010

Stemedica announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company.

(PRWEB) June 11, 2010 -- Stemedica Cell Technologies, Inc., a leader in adult stem cell research and manufacturing, announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company. "Dr. Verkh brings over twenty years of international regulatory and clinical trial experience to Stemedica," said Dr. Nikolai Tankovich, Stemedica's President & Chief Medical Officer. "We are confident that his contribution to our mission to bring innovative products to patients, following FDA guidelines, will be significant."

Dr. Verkh's clinical and regulatory experience includes working for Pfizer, Baxter Bio Sciences, the Alliance Pharmaceutical Corporation and the Alpha Therapeutic Corporation. He has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, peripheral artery disease, hematology, blood disorders and imaging methods. He is author or co-author of over 40 peer-reviewed publications. Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market. "I am honored to be joining Stemedica's management team," said Dr. Verkh, "and am excited to work with the company's leading-edge stem cell technology."

In addition to directing Stemedica's clinical trials within the United States, Dr.
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2

Related biology technology :

1. Stemedica Completes Meeting with the FDA
2. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
3. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
4. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
5. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
6. Stemedica Requests Pre-IND Meeting With FDA
7. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
8. Renowned Stem Cell Researcher Files Study Results With Stemedica
9. CIRM Completes Briefing Visit to Stemedica Cell Technologies
10. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer 
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Oct. 1 /PRNewswire-FirstCall/ - Medicago U.S.A. Inc., a ... a biotechnology company focused on developing highly effective ... and Virus-Like Particles (VLPs), today announced that company ... and U.S. Congressman David Price (D-NC), are holding ...
... Market Presence in PRC Healthcare Laboratory Market -- re> SINGAPORE and HONG KONG, Sept. 30 /PRNewswire-Asia/ -- ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... VANCOUVER, Sept. 30 /PRNewswire-FirstCall/ - Teva Pharmaceuticals Industries Ltd. ... (NASDAQ: OGXI ) announced today the initiation ... (also known as OGX-011/TV-1011) as first line therapy for ... trial is the second of three Phase 3 trials ...
Cached Biology Technology:Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 2Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 4Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 5Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 6Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 7Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 8TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 2TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 3TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 4TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 5TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 6
(Date:4/23/2014)... Wash. -- Like a hungry diner ripping open a ... into electricity must tear open a hydrogen molecule. Now ... holding onto the two halves of its hydrogen feast. ... how to make the catalyst work better for alternative ... scientists have shown precisely where the hydrogen halves end ...
(Date:4/23/2014)... source of a unique rhythmic sound, recorded for decades ... the Antarctic minke whale ( Balaenoptera bonaerensis ). First ... who thought it sounded like a duck, the bio-duck ... Southern Ocean, but its source has remained a mystery, ... of researchers deployed acoustic tags on two Antarctic minke ...
(Date:4/23/2014)... Buenos Aires yesterday, Argentina joins the European Molecular ... The move strengthens the ties between the European ... Argentinian scientists access to EMBL,s world-class facilities and ... since its inception, fostering excellent life science research ... core of EMBL,s mission," says EMBL Director General ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... Institute for Medical Research and a team of collaborators from ... for rheumatoid arthritis. The paper will be published in ... nature of the disease. The gene, dubbed REL, is a ... many roles in the body. The NF-B family seems to ...
... a new colon cancer screening technique created by Northwestern ... could potentially be as or more successful than a ... uses optical technology, called low-coherence enhanced backscattering (LEBS) spectroscopy, ... the rectum. Light shines on the tissue, scatters, and ...
... Techniques and instrumentation initially developed for ExoMars - Europe,s next ... to fly on a NASA mission in 2018, could also ... supply. A major study by the Imperial ... (STFC), aims to use this new technology as an inexpensive ...
Cached Biology News:Researchers identify new risk factor gene for rheumatoid arthritis 2Colon cancer screening technique shows continued promise in new study 2Mars mission could ease Earth's energy supply crisis 2
...
LabFax: Immunochemistry...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
albumin from bovine serum (BSA), 2,4-dinitrophenylated (DNP-BSA)...
Biology Products: